Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: J Pediatr Hematol Oncol. 2020 Oct;42(7):e637–e640. doi: 10.1097/MPH.0000000000001604

Fig 2:

Fig 2:

Average Total Neuropathy Score – 5 for healthy and obese ALL patients during the first 18 months of treatment with vincristine. A) Shown for individual weeks 1–16 and B) shown for individual months 5–18. Analysis with a mixed effect model indicated that subjects who were classified as obese at time of diagnosis had significantly greater neuropathy scores over treatment time p<0.00001